Clinical Trial Update: A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation [Phase 2]

View source ↗

Summary

Phase II multicenter single-arm study evaluating Fulzerasib (IBI351) in combination with Ivonescimab (AK-112) as first-line treatment for advanced or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fulzerasib (IBI351)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: KRAS G12C Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING